Other Vaccines - Israel

Israel

Highlights

The Other Vaccines market in Israel is expected to witness a substantial growth in revenue, with projections indicating that it will reach US$143.70m in 2024.
Furthermore, the market is anticipated to exhibit a steady annual growth rate (CAGR 2024-2029) of 10.37%, ultimately leading to a market volume of US$235.40m by 2029.
When compared globally, it is noteworthy that United States is projected to generate the highest revenue, amounting to US$24.73bn in 2024.
Israel's robust healthcare system and high vaccination rates have positioned it as a global leader in the development and distribution of other vaccines.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Israel, a country in the Middle East, has a growing Other Vaccines market.

Customer preferences: The demand for Other Vaccines in Israel is driven by the country's high healthcare standards and strong emphasis on disease prevention. Additionally, the population's awareness of the importance of vaccination has led to an increase in demand for Other Vaccines.

Trends in the market: The Other Vaccines market in Israel is expected to grow due to the country's aging population and increasing healthcare expenditure. Furthermore, the government's efforts to promote vaccination and prevent the spread of diseases have led to the development of new and innovative vaccines.

Local special circumstances: Israel's unique geopolitical situation has also contributed to the growth of the Other Vaccines market. The country's proximity to regions with high disease prevalence, such as Africa and the Middle East, has led to an increased demand for vaccines that protect against diseases such as yellow fever and meningitis.

Underlying macroeconomic factors: Israel's strong economy and high standard of living have also played a role in the growth of the Other Vaccines market. The country's high healthcare expenditure and investment in research and development have led to the development of new and innovative vaccines that meet the needs of the population.In conclusion, the Other Vaccines market in Israel is expected to continue to grow due to the country's aging population, increasing healthcare expenditure, unique geopolitical situation, and strong economy. The demand for vaccines that protect against diseases prevalent in the region is also expected to contribute to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.